The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).

(MENAFN- GlobeNewsWire - Nasdaq) MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent ...

Growth in the quarter was driven primarily by DARZALEX up 21% to $3.1 billion, ERLEADA up 21% to $784 million, TREMFYA in Immunology, up 4%to $949 million, and SPRAVATO in Neuroscience, up 45% to $297 ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

This quick onset provides hope to patients who may have struggled with depression for years. Moreover, Spravato’s mechanism, targeting glutamate pathways to promote brain connectivity and healing, ...

An estimated 21 million American adults suffer from clinical depression. © 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

Adair County Health System is excited to welcome Johanna Hesseltine, ARNP, PMHNP-BC, to offer mental health services to our community. Johanna is a board-certified psychiatric mental Health Nurse ...

As­traZeneca and Dai­ichi Sankyo’s an­ti­body-drug con­ju­gate En­her­tu is now ap­proved to treat a new sub­set of breast can­cer pa­tients with very low lev­els of HER2 … ...

Eli Lil­ly is dis­con­tin­u­ing a Phase 2 re­lax­in treat­ment can­di­date for heart fail­ure and chron­ic kid­ney dis­ease, a spokesper­son for the com­pa­ny con­firmed to … ...

This quick onset provides hope to patients who may have struggled with depression for years. Moreover, Spravato’s mechanism, targeting glutamate pathways to promote brain connectivity and healing, ...